---
title: "為什麼 2026 年是生物技術行業的復甦之年"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/296384547.md"
description: "該行業的逆風正在消散。這對尋求流動性的風險投資公司以及希望尋找增長故事的股市來説都是好消息，Nilesh Kumar 在一篇客座評論中寫道"
datetime: "2026-08-19T17:20:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296384547.md)
  - [en](https://longbridge.com/en/news/296384547.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296384547.md)
generator: "portal-rs"
---

# 為什麼 2026 年是生物技術行業的復甦之年

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking for growth stories, Nilesh Kumar writes in a guest commentary.

### 相關股票

- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [BIS.US](https://longbridge.com/zh-HK/quote/BIS.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [159849.CN](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [159892.CN](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md)

## 相關資訊與研究

- [一週回顧 | LABU.US 累跌 13.92%，跟隨生物科技板塊走弱](https://longbridge.com/zh-HK/news/298785287.md)
- [Sacituzumab Govitecan 聯合 Pembrolizumab 在一線 PD-L1 高表達轉移性非小細胞肺癌治療中未達到主要終點](https://longbridge.com/zh-HK/news/298830378.md)
- [一週回顧 | ARKG.US 累跌 3.35%，跌破 20 日均線](https://longbridge.com/zh-HK/news/298783949.md)

---
> **免責聲明: 本文僅供參考，不構成任何投資建議。**